Get notified of page updates
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
Advanced ovarian, breast, prostate or pancreatic cancer
Clinicaltrials.gov identifier:NCT04644068
Glossary on
off
About the Study
NOTE: This study is no longer recruiting people.
PETRA is a study of a new, investigational , AZD5305 taken orally, either alone or combined with other anti-cancer therapies in patients with advanced ovarian, breast, or pancreatic cancer with an in one of the following genes: , , , or . The combination available and which group you are assigned to will depend on your cancer type and mutation and when you join the study.
This Study is Open To:
NOTE: This study is no longer recruiting people.
This Study is NOT Open To:
- NOTE: This study is no longer recruiting people.
Advanced ovarian, breast, prostate or pancreatic cancer
Clinicaltrials.gov identifier:NCT04644068